Case Studies
Fast-tracking Market Entry to France
Discover how a Pharmaceutical Company can Cut 18 months off the Standard Timeline.
Fast-tracking Market Entry to France

Are you a biopharmaceutical company eager to launch your first EU-approved drug in France? Don't let the complex and lengthy process of establishing a compliant subsidiary slow you down.
Discover key insights on:
-
How a pharmaceutical company cut 18 months off the standard timeline for establishing its authorized local subsidiary in France.
-
The primary and secondary goals of rapidly setting up a compliant subsidiary and accessing local expertise without unnecessary recruitment.
-
The challenges of obtaining the "Exploitant" license and navigating the complex regulatory landscape in France.
-
The step-by-step process required to establish a subsidiary, including recruiting a Responsible Pharmacist, filing the dossier to ANSM, and more.
-
The successful outcome of entering the French market efficiently while maintaining regulatory compliance.
Download this Case Study
Discover our latest news

White Papers
5 Critical Considerations before your first EMA interaction
Get all the business experience needed for a successful first EMA interaction.

Case Studies
Early Access Programs in France
Explore Proven Strategies for a Quick Market Entry in France.

White Papers
5 Critical Considerations for French Market Entry
Unlock the Secrets to Success in the French Biopharma Market.